Raltegravir雷特格韦,518048-05-0

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Raltegravir

CAS No. : 518048-05-0

MCE 国际站：Raltegravir

产品活性：Raltegravir(MK0518)是HIV整合酶（IN）抑制剂。

研究领域：Metabolic Enzyme/Protease  |  Anti-infection

作用靶点：HIV Integrase  |  HIV

In Vitro: PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC₅₀ of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC₅₀ of 200 nM, indicating a appr twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. S217Q PFV IN is as sensitive to Raltegravir as the WT enzyme. Raltegravir is metabolized by glucuronidation, not hepatically. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31±20 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEMx174 cells, with an IC₉₅of 6 nM. Raltegravir metabolism occurs primarily through glucuronidation. Drugs that are strong inducers of the glucuronidation enzyme, UGT1A1, significantly reduce Raltegravir concentrations and should not be used. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. Raltegravir does not induce CYP3A4 RNA expression or CYP3A4-dependent testosterone 6-β-hydroxylase activity. Raltegravir cellular permeativity is reduced in the presence of magnesium and calcium. Raltegravir and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs efficiently block viral replication. In acutely infected human lymphoid CD4⁺ T-cell lines MT-4 and CEMx174, SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC₉₀ in the low nanomolar range.

In Vivo: Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate shows an undetectable viral load following Raltegravir monotherapy.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Targeted Diversity Library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Off-patent Drug Library  |  Cytokine Inhibitors Library  |  Chloroquine  |  Doxorubicin hydrochloride  |  5-Fluorouracil  |  Q-VD-OPh  |  Valproic acid  |  Panobinostat  |  Shikonin  |  Hydroxyurea  |  Probenecid  |  Kaempferol  |  Plerixafor  |  Dimethyl fumarate  |  Birinapant  |  Maraviroc  |  Baicalin  |  Flavopiridol  |  Ritonavir  |  Ivermectin  |  Fasudil Hydrochloride  |  Ebselen  |  Rolipram  |  Betulinic acid  |  CK-666  |  Oleanolic Acid  |  Lysozyme from chicken egg white  |  ONX-0914  |  Dolutegravir

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds